<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448305</url>
  </required_header>
  <id_info>
    <org_study_id>CT 4002</org_study_id>
    <secondary_id>EudraCT-Nr. 2006-002221-23</secondary_id>
    <nct_id>NCT00448305</nct_id>
  </id_info>
  <brief_title>EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients</brief_title>
  <official_title>An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and tolerability of a therapy&#xD;
      with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for&#xD;
      patients with relapsed or metastatic triple receptor negative breast cancer (a special&#xD;
      subgroup of breast cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is still a major public health problem worldwide, as it is by far the most&#xD;
      frequent neoplasm in women. In recent years so-called &quot;profiling of breast cancer&quot; with&#xD;
      expression arrays has become common and it was suggested that the results will allow&#xD;
      individualization of care. Breast cancer may now be subclassified into luminal, basal, and&#xD;
      HER-2 subtypes with distinct differences in prognosis and response to therapy. About 80% of&#xD;
      all basal-like-breast cancers possess a so-called &quot;triple-receptor-negative&quot; phenotype.&#xD;
&#xD;
      Patients with &quot;triple receptor negative breast cancer&quot; have a complete absence of hormone&#xD;
      receptors incl. HER-2, an aggressive clinical course and a paucity of treatment options. The&#xD;
      only therapeutic option is chemotherapy and in this respect the choice of cytostatic agents&#xD;
      is limited. Against this background, the study tries to find another therapeutic option by&#xD;
      combining a vascular-disrupting activity with the cytostatic effects of paclitaxel in the&#xD;
      study drug EndoTAG-1.&#xD;
&#xD;
      Comparison: EndoTAG-1 + paclitaxel (combination therapy) and EndoTAG-1 (monotherapy) in&#xD;
      comparison to paclitaxel (control group)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-month progression free survival (PFS) rate</measure>
    <time_frame>4 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>median progression free survival (PFS) time</measure>
    <time_frame>progression of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-month survival rate</measure>
    <time_frame>4-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median overall survival time</measure>
    <time_frame>Withdrawal or death of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain assessment</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit assessment via quality of life (QoL)Scale</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory values</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose variations</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTAG-1 + Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTAG-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1 + paclitaxel</intervention_name>
    <description>EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1</intervention_name>
    <description>EndoTAG-1 44 mg/m² twice weekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 90 mg/m² weekly</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven triple-receptor-negative metastatic or relapsed breast cancer&#xD;
&#xD;
          -  Minimum interval of 6 months after the end of any previous taxane- containing&#xD;
             chemotherapy regimen&#xD;
&#xD;
          -  At least one tumor lesion measurable according to RECIST criteria&#xD;
&#xD;
          -  Gender: female&#xD;
&#xD;
          -  Age &gt;= 18 years old&#xD;
&#xD;
          -  Negative pregnancy test (females of childbearing potential)&#xD;
&#xD;
          -  Willingness to perform double-barrier-contraception during study and for 6 months post&#xD;
             chemotherapy treatment&#xD;
&#xD;
          -  ECOG performance status 0, 1 or 2&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 1 previous chemotherapeutic treatment for metastatic or relapsed disease&#xD;
&#xD;
          -  Major surgery &lt; 4 weeks prior to enrollment&#xD;
&#xD;
          -  Immunotherapy &lt; 2 weeks prior to enrollment&#xD;
&#xD;
          -  Severe pulmonary obstructive or restrictive disease&#xD;
&#xD;
          -  Uncontrolled inflammatory disease (autoimmune or infectious)&#xD;
&#xD;
          -  Clinically significant cardiac disease (NYHA stadium &gt; 2)&#xD;
&#xD;
          -  Laboratory tests (hematology, chemistry) outside specified limits&#xD;
&#xD;
          -  Pregnancy or nursing status&#xD;
&#xD;
          -  Known positive HIV testing&#xD;
&#xD;
          -  Known hypersensitivity to any component of the EndoTAG-1 or taxane formulations&#xD;
&#xD;
          -  History of malignancy other than breast cancer &lt; 5 years prior to enrollment, except&#xD;
             skin cancer (i.e. basal or squamous cell carcinoma) treated locally&#xD;
&#xD;
          -  Known progressive cerebral metastasis (patients with cerebral metastases in a stable&#xD;
             state or after successful surgical or radiological treatment are allowed to&#xD;
             participate in the study)&#xD;
&#xD;
          -  History of active or significant neurological disorder or psychiatric disorder that&#xD;
             would prohibit the understanding and giving of informed consent, or would interfere in&#xD;
             the clinical and radiological evaluation of central nervous system during the trial&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational not marketed drug within 30 days prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Awada, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000 Brussels, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cente Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jour Centre Henri Kaplan</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vedanta Institute of Medical Science</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Searoc Cancer Center</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeshore Hospital</name>
      <address>
        <city>Kochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaushalya Medical Foundation</name>
      <address>
        <city>Thane</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Centrum Onkologii</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. M. Sklodowskiej-Curie</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut im. M. Sklodowskiej-Curie</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Grupowa Specjalistyczna</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii Adadmii Medycznej</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology &quot;Prof. Dr. Al. Trestioreanu&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology &quot;Prof. Dr. I. Chiricuta&quot;</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Medical Oncology</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital Sibiu</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Clinic &quot;Oncomed&quot;</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnepropetrovsk State Medical Acedamy</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Radiology of Acedamy of Medical Sciences</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Abdominal Surgery</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut of Oncology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Department</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivne Regional Oncological Dispensary</name>
      <address>
        <city>Rovno</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumy Reginal Oncology Center</name>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Uzhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>India</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2007</study_first_posted>
  <last_update_submitted>January 3, 2012</last_update_submitted>
  <last_update_submitted_qc>January 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>relapsed</keyword>
  <keyword>triple-receptor negative</keyword>
  <keyword>EndoTAG-1</keyword>
  <keyword>metastatic or relapsed breast neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

